Skip to main content
Nxera Pharma Co., Ltd. logo

Nxera Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 4565 ISIN · JP3431300007 LEI · 2138004M62BFNJMR2Z82 T Manufacturing
Open in API
Filings indexed 113 across all filing types
Latest filing 2024-05-09 Interim / Quarterly Rep…
Country JP Japan
Listing T 4565

About Nxera Pharma Co., Ltd.

https://www.nxera.life/

Nxera Pharma Co., Ltd. (formerly Sosei Group Corp.) is a technology-driven biopharmaceutical company focused on the discovery and early development of novel medicines. The company utilizes its proprietary StaR® technology and world-leading expertise in G protein-coupled receptor (GPCR) structure-based drug design (SBDD) to create therapeutics for diseases with high unmet medical needs. By integrating advanced science and technology, Nxera Pharma develops its internal pipeline and collaborates with partners to accelerate the creation of life-changing treatments for patients worldwide. Its mission is to invest in science and technology to accelerate the development of these medicines.

Recent filings

Filing Released Lang Actions
四半期報告書－第35期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management analysis (MDA), and business updates for Nxera Pharma Co., Ltd. (formerly Sosei Group Corporation). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. Q1 2024
2024-05-09 Japanese
有価証券届出書（参照方式）
Capital/Financing Update Classification · 95% confidence The document explicitly identifies itself on the cover page as an "有価証券届出書" (Yūka Shōken Todokedesho), which translates to a Securities Registration Statement in Japanese regulatory filings. This type of filing is used to register securities offerings with the regulatory body (Kanto Local Finance Bureau in this case). The content details the offering of common stock via Restricted Stock Units (RSUs) as compensation, including the number of shares, expected total value, allocation method (to employees/executives), and future determination dates for price and quantity. This structure aligns with filings related to capital raising or issuance of securities, which in the US context often corresponds to a registration statement (like an S-1 or S-3, though here it's a specific Japanese form). Among the provided codes, 'CAP' (Capital/Financing Update) is the closest fit for a filing detailing a specific issuance of shares for compensation/financing purposes, although 'SHA' (Share Issue/Capital Change) is also relevant. However, the formal nature and comprehensive detail of a 'Securities Registration Statement' strongly suggest a primary financing/capital event registration. Given the options, 'CAP' covers financing activities, and this is a registration for issuing shares to employees via RSU compensation, which is a form of capital structuring/financing. If a more specific code for registration statements existed, it would be preferred, but 'CAP' is the best fit for a formal filing detailing a share issuance/compensation plan that involves capital structure changes.
2024-04-17 Japanese
有価証券届出書（参照方式）
Capital/Financing Update Classification · 98% confidence The document explicitly identifies itself on the cover page as a "有価証券届出書" (Yūka Shōken Todokedesho), which translates to a Securities Registration Statement. This type of filing is used in Japan to register securities offerings with the financial authorities (in this case, the Kanto Local Finance Bureau Director - 関東財務局長). The content details the specifics of a new stock issuance (新規発行株式) related to a Restricted Stock Unit (RSU) compensation plan, including the number of shares, expected total value, and allocation method. This is a mandatory filing required before offering securities to the public or specific parties, which aligns closely with the purpose of a registration statement, often associated with capital raising activities. Among the provided codes, 'CAP' (Capital/Financing Update) is the closest fit for a document detailing a new share issuance for compensation purposes, although 'RPA' or 'RNS' might be considered if it were merely an announcement. However, since this is the full, detailed registration document itself, 'CAP' is the most appropriate classification for a significant financing/capital structure event filing.
2024-04-17 Japanese
有価証券届出書（参照方式）
Capital/Financing Update Classification · 98% confidence The document explicitly identifies itself on the cover page as a "有価証券届出書" (Yūka Shōken Todokedesho), which translates to a Securities Registration Statement. This type of filing is used in Japan to register securities offerings with the financial authorities (here, the Kanto Local Finance Bureau Director). The content details the offering of common stock via a Restricted Stock Unit (RSU) plan to directors/executives, including the number of shares, issue price, and purpose. This is a specific type of filing related to capital raising or issuance, which aligns most closely with the 'Capital/Financing Update' (CAP) category, as it details the terms of a new share issuance (though for compensation purposes, it is fundamentally a financing/capital structure event being registered). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA). Given the specific nature of registering a securities offering, CAP is the most appropriate fit among the provided codes.
2024-04-17 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and explicitly states in Section 1 that it is being filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the company's 34th Annual General Meeting (AGM) held on March 27, 2024. Section 2 details the resolutions, including changes to the articles of incorporation (name change to Nextera Pharma, head office relocation, and board size increase) and the election of directors, along with the voting results. Since this document reports the official results of shareholder votes from a general meeting, it directly corresponds to the Declaration of Voting Results & Voting Rights Announcements category.
2024-03-27 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type, as they do not contain the actual financial statements themselves. FY 2023
2024-03-27 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.